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Risk Factors for Cerebral Embolization after Carotid Artery Stenting with
Embolic Protection – A DW–MRI Study in 827 Patients
Klaudija Bijuklic1, Andreas Wandler2, Thilo Tuebler3, Joachim Schofer4
1Medical Care Center, Hamburg, Germany, 2Medical Care Center Prof Mathey,
Prof Schofer, Hamburg, Germany, 3Medical Care Center Prof. Mathey, Prof.
Schofer, Hamburg, Germany, 4Medicare center Prof Mathey, Prof Schofer,
Hamburg University Cardiovascular Center, Hamburg, Germany
Background: Carotidendarterectomy and CAS appear to have similar overall perioper-
ative stroke rates, which, however, may differ in specific patient subgroups. Knowledge
of the risk factors for cerebral embolic events during CAS may impact treatment decisions
for the individual patient, but have not been extensively studied.Aim of the study was to
evaluate the risk factors for cerebral embolization after carotid artery stenting with
embolic protection.
Methods: Out of 837 consecutive patients undergoing CAS with cerebral embolic
protection pre- and post-procedural diffusion weighted magnetic resonance imaging
(DW-MRI) was performed for evaluation of new cerebral ischemic lesions in 728 patients
(86.9%). Multivariate logistic regression analyses were performed to identify factors
predictive for embolic events.
Results: New ischemic lesions were found in 32.8 % of the patients. Age, hypertension,
lesion length, lesion excentricity, and aortic arch type III were significantly associated
with new ischemic lesions, calcified lesions were negatively associated. In 25% of patients
with embolic events lesions were also found in the contralateral hemisphere. Predictive
factors for contralateral lesions were age,  50% stenosis of the contralateral internal
carotid artery, and an aortic arch type II, with a trend for aortic arch type III.
Conclusions: Age, hypertension, lesion morphology, and aortic arch type were predic-
tive for procedural related cerebral embolic events during embolic protected CAS. Age,
significant contralateral carotid stenosis and complex aortic arch type were predictive for
contralateral ischemic events. These findings may help to find the optimal treatment
decision for the individual patient with carotid artery stenosis.
TCT-2
Peri-procedural Outcomes After Carotid Artery Stenting with the First 15,000
Patients Enrolled in the SAPPHIRE Worldwide Study
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Richard Smalling5, Donald Heck6
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Background: Further study is needed to determine which patient characteristics and
lesion criteria derive the greatest benefit from carotid artery stenting (CAS). SAPPHIRE
Worldwide is a large scale multicenter post-approval study to evaluate CAS with distal
embolic protection using the Cordis PRECISE® Nitinol Stent and ANGIOGUARD™
XP/RX Emboli Capture Guidewire.
Methods: Patients were enrolled with either symptomatic stenosis 50% or asymptom-
atic stenosis 80% and considered at high risk for surgery. Inclusion criteria included
adherence to current FDA-approved labeling with these devices. The primary endpoint of
major adverse events (MAE) at 30 days included any death, myocardial infarction or
stroke.
Results: Enrollment began October, 2006 and is ongoing. Data were previously reported
on 10,008 patients, of whom 2,963 (30%) were symptomatic and 7,045 (70%) were
asymptomatic. Overall, the MAE rate at 30 days was 4.5% (death 1.3%, MI 0.6%, stroke
3.3%). There was a significant increase in the combined rate of stroke or death at 30 days
between symptomatic and asymptomatic patients (6.2% vs. 3.8%, p0.0001), and
patients 75 years of age and older compared to younger patients (5.9% vs. 3.3%,
p0.0001). The 30-day stroke or death rate did not differ significantly among operator
experience or volume of centers. To date, 15,000 patients have been enrolled and
completed 30-day follow-up. Final data will be available and presented on the 15,000
patients at time of presentation.
Conclusions: These data compare favorably to other reports of CAS in a high-surgical
risk population and are similar to results recently reported in the CREST trial comparing
CAS to surgery in a non-high surgical risk population.
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Early results of multicenter, prospective trial of TEVAR for blunt thoracic
aortic injury (RESCUE Trial)
Ali Khoynezhad1, Ali Azizzadeh2, Carlos Donayre3, Alan Matsumoto4, Rod White3
1Cedars-SInai Medical Center, Los Angeles, CA, 2University of Texas at Houston,
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Background: Outcome of patients with blunt aortic injury undergoing endovascular
repair is poorly understood. The aim of this study is to evaluate the early outcome of
patients undergoing TEVAR for blunt aortic injuries.
Methods: A prospective, non-randomized, multicenter trial using Medtronic Valiant
Captivia was conducted at 20 sites. 50 patients with blunt aortic injury were enrolled
between April 2010 and January 2012. The primary endpoint was 30-day all-cause
mortality. Secondary endpoints were 30-day adverse events related to the procedure,
device or aorta, aortic-related mortality and successful device delivery/deployment.
Results: 38/50(76%) were male with mean age of 40.7 17.4 years. 52 stent grafts were
implanted within a median of 1.0 day following injury (mean 1.8 4.0 days). 70%(35/50)
of aortic injuries were grade 3 or higher. Mean injury severity score was 37.6  14.3.
38/52 (74%) of stent grafts were 28 mm. The left subclavian artery was completely
covered in 40% of patients (20/50) and partially covered in 18% of patients (9/50). One
patient with partial coverage underwent subclavian artery revascularization. Cerebral
spinal fluid was drained in 2 patients. The median procedure time was 90.5 minutes, and
median hospital stay was 11 days. There was 100% successful device delivery/
deployment.
Conclusions: Based on the early outcomes, TEVAR using the Valiant Captivia appears
to be a promising treatment modality for blunt thoracic aortic injuries.
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Impact of Catheter Fragmentation followed by Local Intrapulmonary
Thrombolysis in Acute High risk Pulmonary Embolism as Primary Therapy:
Acute and Long term outcomes
Bishav Garg1, Shibba Chhabra1, Naved Aslam1, Rohit Tandon1, Naresh Sood1,
Gurpreet Wander1
1Dayanand Medical College & Hospital Unit Hero DMC Heart Institute,
Ludhiana, Punjab
Background: Massive Pulmonary embolism (PE) requires prompt reperfusion to prevent
progressive hemodynamic decline and death. We report our single center experience on
immediate and long-term outcomes in high risk PE patients treated with mechanical
fragmentation followed by intrapulmonary thrombolysis as a primary therapy.
Methods: 50 consecutive high risk PE patients defined as shock index (heart rate /systolic
blood pressure) 1, 50% pulmonary arterial obstruction and pulmonary hypertension
(mean pulmonary arterial pressures (PAP) 25 mm Hg) underwent emergent mechanical
reperfusion by standard pigtail catheter; followed by intrapulmonary infusion of urokinase
over 24 hours. After discharge, transthoracic echocardiography (TTE) was done at 3. 6
and 12 months.
Results: Mechanical thrombectomy restored antegrade flow in all patients. The average
heart rate, mean PAP, Miller score, Shock index decreased significantly from 125 
18bpm, 41 8 mmHg, 20 5, 1.32 0.3 to 93 13 bpm, 24 7 mmHg, 5 2, 0.79
0.2 respectively after 24 hrs (P  0.0001). A significant increase was observed in
mean blood pressure and O2 saturation (78 12 mm Hg vs. 92 11 mm Hg, 90% 
7% vs. 98%  2% respectively p  0.0001). Inhospital mortality was 4% (2/50 pts)
and major bleeding complications (local hematoma requiring blood transfusion) were
seen in 2 patients. Sequential TTE based estimation of pulmonary arterial systolic
pressure showed a statistically significant linear trend of reduction from 62 11 mm
Hg at presentation to 23 6 mm Hg at 12 months.
Conclusions: Our results show that mechanical fragmentation followed by intrapulmo-
nary thrombolysis can be offered as a primary therapy for high risk PE patients in
experienced centers, similar to approach with coronary revascularization.
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Efficacy of Cardiatis Multilayer Flow Modulator in Peripheral and
Visceral Aneurysms Repair: Italian Multicenter Registry Results at One
Year Follow Up
maria antonella ruffino1, claudio rabbia1
1San Giovanni Battista Hospital, Torino, Italy
Background: to show results of Cardiatis Multilayer Stent (CMPS) in peripheral (PAA)
and visceral aneurysms (VAA) repair with/without collateral branches after one year FU.
Methods: between May 2009 and June 2010, 54 patients with PAA (35) and VAA (19)
were treated with CMPS. Early (30 days), 6 months and 12 months results were analysed
in terms of aneurysm thrombosis, stent and side branches patency, and shrinkage. All data
were recorded in the Italian Registry of Cardiatis Procedures.
Results: intraoperative immediate technical success was achieved in all the cases.
Clinical success was evaluated with CT-angiography. Complete aneurysm thrombosis
rate at 1,6, and 12 month FU was 86.5% (45/52 patients), 94.2% (49/52 patients), and
93.3% (42/45 patients) respectively. Side branches patency rate was 98.1 (51/52) at 1 and
6 months, and 97.8% (44/45) at 12 months, with a stent patency rate of 94.2% (49/52) at
1 and 6 months, and 91.1% (41/45) at 12 months. We could analyse shrinkage at each
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